4.6 SOS/VOD Diagnostic Criteria, Surveillance & Defibrotide Therapy
Key Takeaways
- Baltimore, modified Seattle, and adult/pediatric EBMT criteria differ in timing and bilirubin requirements; pediatric and late-onset disease can be anicteric.
- Trend weight, fluid balance, abdominal/liver findings, bilirubin, renal/pulmonary status and platelet consumption using the program surveillance plan; no one imaging sign replaces clinical criteria.
- Supportive care limits additional hepatic injury and manages fluid/organ complications while avoiding nephrotoxins and unsafe fluid removal.
- Defibrotide is FDA-approved for hepatic VOD/SOS with renal or pulmonary dysfunction after HCT. Use 6.25 mg/kg IV every 6 hours per label for at least 21 days, continuing until resolution or 60 days maximum; monitor bleeding and contraindicated systemic anticoagulant/fibrinolytic therapy.
1. Diagnostic Criteria Frameworks: Baltimore, Seattle & EBMT
Because liver biopsy carries severe bleeding risks in thrombocytopenic transplant recipients, SOS/VOD is primarily a clinical syndromic diagnosis based on validated scoring frameworks.
+---------------------------------------------------------------------------------------------------+
| SOS / VOD DIAGNOSTIC CRITERIA COMPARISON |
| |
| MODIFIED SEATTLE CRITERIA (Within Day +20): |
| Requires at least 2 of the following 3 features: |
| 1. Hyperbilirubinemia (Total Bilirubin >= 2.0 mg/dL / 34 µmol/L) |
| 2. Hepatomegaly (usually painful) OR Right Upper Quadrant (RUQ) Pain |
| 3. Unexplained Weight Gain >= 2% from baseline due to fluid retention |
| |
| BALTIMORE CRITERIA (Within Day +21): |
| MANDATORY: Hyperbilirubinemia (Total Bilirubin >= 2.0 mg/dL / 34 µmol/L) |
| PLUS at least 2 of the following: |
| 1. Painful Hepatomegaly |
| 2. Ascites |
| 3. Weight Gain >= 5% from pre-conditioning baseline |
| |
| EBMT UPDATED CRITERIA (Adults & Pediatrics): |
| * Classical SOS: Onset <= Day 21 |
| * Late-Onset SOS: Onset > Day 21 (common with RIC, busulfan PK, or inotuzumab) |
| * Pediatric Criteria: Does NOT require hyperbilirubinemia (allows diagnosis in anicteric cases)!|
+---------------------------------------------------------------------------------------------------+
Detailed Diagnostic Criteria Comparison Table
| Diagnostic System | Timing Threshold | Bilirubin Requirement | Weight Gain Threshold | Additional Mandatory / Optional Criteria |
|---|---|---|---|---|
| Modified Seattle | Within Day +20 post-HCT | >= 2.0 mg/dL (34 µmol/L) (as 1 of 3 criteria) | >= 2% above pre-transplant baseline | Requires at least 2 of 3 criteria: Bilirubin >= 2.0, Weight gain >= 2%, or Hepatomegaly / RUQ pain. |
| Baltimore | Within Day +21 post-HCT | MANDATORY: >= 2.0 mg/dL (34 µmol/L) | >= 5% above pre-transplant baseline | Requires Bilirubin >= 2.0 PLUS at least 2 of: Hepatomegaly, Ascites, or Weight gain >= 5%. |
| EBMT adults | Classical <=21 d or late-onset >21 d | Classical criteria require bilirubin >=2.0 mg/dL | >5% is one feature | Classical: bilirubin plus 2 of painful hepatomegaly, weight gain >5%, or ascites. Late-onset: classical criteria, histologic proof, or at least 2 SOS features plus hemodynamic/ultrasound evidence. |
| EBMT pediatrics | No fixed day limit | Hyperbilirubinemia is not required; a rising pattern is one feature | Persistent unexplained gain despite diuretics or >5% is one feature | At least 2 pediatric features: consumptive/transfusion-refractory thrombocytopenia, qualifying weight gain, hepatomegaly, ascites, or qualifying bilirubin rise. Apply the complete pediatric definition. |
2. Management and Defibrotide
Immediately review conditioning and hepatotoxic exposures, avoid additional liver injury where possible, manage sodium/fluid balance with frequent reassessment, and support renal, pulmonary, coagulation, and hemodynamic complications. Diuresis, paracentesis, renal replacement, or critical-care support depends on physiology; an arbitrary fluid cap is unsafe.
Defibrotide (Defitelio) is FDA-approved for hepatic VOD/SOS with renal or pulmonary dysfunction after HCT. The labeled dose is 6.25 mg/kg IV every 6 hours, infused over 2 hours, based on pre-conditioning baseline weight. Treat for at least 21 days; if signs and symptoms persist, continue until resolution or a maximum of 60 days. Do not initiate in active bleeding, discontinue for significant bleeding, and do not give with systemic anticoagulant or fibrinolytic therapy except routine central-line maintenance addressed by the label. Hold around invasive procedures according to the prescribing information and program plan. Defibrotide can cause hemorrhage; it does not provide bleeding-free fibrinolysis.
3. Diagnostic Workup and Hemodynamic Assessment
Imaging
Doppler ultrasonography can support the assessment and help evaluate biliary obstruction, vascular flow, ascites and other competing causes. Findings such as hepatomegaly, ascites, gallbladder-wall edema, altered portal flow or hepatic-artery indices are neither uniformly present nor independently diagnostic. Interpret them with timing, serial weight/fluid balance, bilirubin trajectory, platelet consumption and organ dysfunction.
When the diagnosis remains uncertain, specialist-selected testing may include advanced ultrasound scoring, elastography, hemodynamic assessment or transjugular biopsy. The hepatic venous pressure gradient is calculated as wedged hepatic venous pressure minus free hepatic venous pressure. Elevated gradients can support portal hypertension/SOS, but no invasive result replaces the complete clinical framework. A transjugular approach may lower peritoneal bleeding risk compared with percutaneous biopsy; it does not eliminate hemorrhage or sampling risk.
4. Defibrotide Safety Translation
Use the current label-directed regimen and transplant order set. Before every dose, review bleeding, concomitant systemic anticoagulant/fibrinolytic therapy, planned procedures, line compatibility and product preparation/expiration. A central-line maintenance flush is handled according to the specific label and program; it is not permission for therapeutic anticoagulation. Stop and escalate significant bleeding or hypersensitivity and document response across bilirubin, weight/fluid status and renal/pulmonary dysfunction.
5. Bedside Surveillance and Supportive Care
- Obtain same-scale weights and accurate intake/output at the center’s ordered frequency; trend abdominal girth, ascites, right-upper-quadrant pain and respiratory status.
- Trend bilirubin/liver tests, creatinine, urine output, oxygen need, blood counts, coagulation and transfusion response. Do not use one platelet or fibrinogen goal for every patient.
- Provide patient-specific sodium/fluid management and diuresis while protecting renal perfusion. Review nephrotoxic and hepatotoxic drugs with the team rather than stopping essential therapy independently.
- Escalate rapid weight gain, falling urine output, increasing oxygen need, hypotension, bleeding, confusion or other multiorgan dysfunction promptly.
6. Managing Bleeding Risk During Defibrotide Therapy
Defibrotide's profibrinolytic and endothelial-protective activity is inseparable from its bleeding risk, and the therapy runs for weeks in a patient who is already thrombocytopenic, which makes bleeding surveillance a continuous nursing responsibility rather than an admission check.
Concurrent systemic anticoagulant or fibrinolytic therapy is contraindicated, so the medication list is reviewed at initiation and whenever a new order is written. Prophylactic anticoagulation ordered by another service is a real and recurring hazard.
Therapy is interrupted around bleeding and procedures. Clinically significant bleeding requiring intervention prompts holding the drug, and doses are withheld before invasive procedures and resumed afterward according to the label and the ordering team. Nurses are frequently the first to know a procedure has been scheduled, so surfacing it early prevents a dose given at the wrong time.
Surveillance is systematic. Assess mucosal surfaces, catheter exit sites, urine, stool, sputum, and neurologic status each shift; trend hemoglobin and platelets against transfusion history rather than in isolation; and treat a new headache, altered mental status, or unexplained hemoglobin drop as potential bleeding until evaluated.
Bedside care reduces avoidable trauma. Use soft oral care, avoid rectal medications and temperatures, minimize venipuncture, hold pressure longer than usual, and coordinate line care with the platelet count.
A 34-year-old patient on Day +12 post-allogeneic peripheral blood stem cell transplant with busulfan/cyclophosphamide conditioning exhibits a 6% weight gain above pre-transplant baseline, right upper quadrant abdominal tenderness with a liver edge palpable 4 cm below the right costal margin, new shifting abdominal dullness, and a total serum bilirubin of 3.8 mg/dL. Based on Baltimore and Modified Seattle criteria, what diagnosis is established?
The transplant team is preparing to initiate defibrotide for a patient with newly diagnosed severe SOS/VOD. Which clinical scenario represents an absolute contraindication to administering defibrotide?
What is the recommended dosing, administration schedule, and minimum treatment duration for defibrotide in the management of post-transplant Sinusoidal Obstruction Syndrome?